APC
WVE icon

Aspire Private Capital’s Wave Life Sciences WVE Stock Holding History

Aspire Private Capital’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150
Closed -$749 – 723
2024
Q2 		$749 Buy
+150
New +$856 ﹤0.01% 610

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aspire Private Capital's WVE Position: Q3 2024 in Review

Aspire Private Capital sold out of Wave Life Sciences (WVE) in Q3 2024, closing a stake of 150 shares — an estimated $749 sold.

Aspire Private Capital first reported a position in WVE in Q2 2024 and held it in 1 quarter. The position peaked at $749 in Q2 2024. 162 funds tracked by Wall St. Rank hold WVE as of Q3 2024.

  • Aspire Private Capital reported no remaining Wave Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Aspire Private Capital sold 150 Wave Life Sciences shares in Q3 2024, an estimated $749.
  • Aspire Private Capital first reported a position in Wave Life Sciences in Q2 2024 and held it in 1 quarter.
  • Aspire Private Capital's Wave Life Sciences position peaked at $749 in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Wave Life Sciences as of Q3 2024.

Based on Aspire Private Capital's 13F filing for Q3 2024, filed 25 Oct 2024.